Trial reportJournal of gynecologic oncology2026
Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial.
Trial report in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07055399 (Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Chemotherapy-eclipse for Locally Advanced Cervical Cancer：A Single-arm, Open-label, Phase II Trial), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Chemotherapy-eclipse for Locally Advanced Cervical Cancer：A Single-arm, Open-label, Phase II Trial
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundNeoadjuvant treatments combining anti-programmed cell death 1 (PD-1) inhibitors with chemotherapy induce higher pathologic response rates than chemotherapy alone in patients with locally advanced cervical cancer (LACC). A dual blocker that targets PD-1 and cytotoxic T lymphocyte-associated protein-4, paired with de-escalated chemotherapy, may improve treatment efficacy while reducing toxicity. This study aims to evaluate the efficacy and safety of neoadjuvant iparomlimab and tuvonralimab in conjunction with reduced courses of chemotherapy for LACC.
methodsIn this multi-center, single-arm, open-label, phase II trial, patients with histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma are eligible. A total of 43 patients diagnosed with International Federation of Gynecology and Obstetrics 2018 stage IB3, IIA2, IIB, or IIIC1r will receive iparomlimab and tuvonralimab (5 mg/kg, intravenously), nab-paclitaxel (60 mg/m², intravenously), and cisplatin (75-80 mg/m², intravenously) for the first cycle. Then, 2 additional cycles of iparomlimab and tuvonralimab (5 mg/kg, intravenously) were followed at 3-week intervals. After finishing 3 cycles of neoadjuvant treatment, patients who exhibit a complete response (CR) or partial response (PR) will proceed to radical surgery, and subsequent adjuvant therapy will be guided by the National Comprehensive Cancer Network guidelines. Conversely, patients with stable or progressive disease will transition to concurrent chemoradiotherapy. The primary endpoint is the pathological CR. Secondary endpoints include the objective response rate, event-free survival, major PR, disease-free survival rate, and safety. Additionally, the exploratory endpoint will focus on identifying predictive biomarkers associated with tumor response.
trial registrationClinicalTrials.gov Identifier: NCT07055399.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.